CHEAR Faculty Affiliate Featured in Washington Post Article

David Hutton, PhD, a professor of global health at the University of Michigan School of Public Health, was recently quoted in The Washington Post about his work modeling the costs and benefits of Beyfortus, a newly approved antibody treatment that prevents respiratory syncytial virus (RSV) illness in infants and high risk toddlers. He found that the treatment is clearly cost effective for high-risk babies but, depending on the manufacturer’s final price, may or may not be cost-effective for all infants.

He also presented the cost-effectiveness of RSV vaccines in older adults at the CDC's Advisory Committee on Immunization Practices (ACIP) in late June. The committee voted in favor of RSV vaccination in adults 60 and older with consultation from their doctors, and their recommendation was accepted by the CDC director. The vaccines are expected to be available this fall. 

Read Dr. Hutton's interview with the University of Michigan School of Public Health by clicking here.